October 22, 2016 11:18 PM ET


Company Overview of Kolltan Pharmaceuticals, Inc.

Company Overview

Kolltan Pharmaceuticals, Inc. discovers and develops novel antibody-based drugs targeting receptor tyrosine kinases (RTK) for the treatment of cancer and other diseases. Its lead product candidate includes KTN3379, an antibody targeting the ErbB3 RTK, which is in Phase I clinical trials for adult patients with advanced solid tumors. The company is also developing KTN0158, a KIT RTK inhibitor for the treatment of neurofibromatosis type 1 and other inflammatory diseases; and KIT-ADC, an antibody drug conjugate for oncology treatment, as well as a range of research programs targeting RTKs. Kolltan Pharmaceuticals, Inc. was founded in 2007 and is based in New Haven, Connecticut.

300 George Street

Suite 530

New Haven, CT 06511

United States

Founded in 2007

37 Employees





Key Executives for Kolltan Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 61
Co-Founder and Chairman of the Board
Age: 51
Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist and Director
Age: 71
Chief Financial & Business Officer and Senior Vice President
Age: 50
Senior Vice President of Translational Medicine & Product Development
Age: 50
Compensation as of Fiscal Year 2016.

Kolltan Pharmaceuticals, Inc. Key Developments

Kolltan Pharmaceuticals, Inc. Presents at JMP Securities 2016 Life Sciences Conference, Jun-22-2016 02:30 PM

Kolltan Pharmaceuticals, Inc. Presents at JMP Securities 2016 Life Sciences Conference, Jun-22-2016 02:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.

Kolltan Pharmaceuticals, Inc. Announces Preclinical Data Relating to its KTN3379 and KTN0073 Drug Development Programs

Kolltan Pharmaceuticals, Inc. announced the presentation of preclinical data relating to its KTN3379 and KTN0073 drug development programs at the AACR Annual Meeting, taking place in New Orleans, Louisiana, April 16-20, 2016. This new preclinical data with KTN3379, along with emerging clinical results to date, support its plans to initiate a Phase 2 study in squamous cell tumors of the head and neck. KTN0073 is a humanized, IgG2 monoclonal antibody that inhibits Met-dependent tumor growth in preclinical models when activated by HGF, Met gene amplification, or mutations in exon 14. The poster presentation highlighted the following data and results: KTN0073 was identified as a potent anti-Met antibody with broad anti-tumor activity in HGF-driven and Met amplified tumors; KTN0073 induced potent degradation of oncogenic exon 14-mutant Met, which propagates prolonged Met signaling due to a defect in receptor degradation; Conversion of the antibody from IgG1 to IgG2 surprisingly resulted in enhanced anti-tumor activity invitro and in vivo; and KTN0073 demonstrated broad anti-tumor activity through multiple mechanisms of action in HGF-driven, Met-amplified, and exon 14-mutated tumors. KTN3379 is a human monoclonal antibody designed to block the activity of ErbB3 (HER3), a receptor tyrosine kinase (RTK) that belongs to the epidermal growth factor receptor, or EGFR, family. ErbB3 is believed to be an important receptor regulating cancer cell growth and survival. ErbB3 is expressed in many cancers, including head and neck, breast, lung, gastric, and melanoma. Kolltan is conducting multiple clinical trials evaluating KTN3379 in the treatment of solid tumors (NCT02014909, NCT02456701, and NCT02473731).

Kolltan Pharmaceuticals, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-11-2016 12:00 PM

Kolltan Pharmaceuticals, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-11-2016 12:00 PM. Venue: The Waldorf Astoria, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kolltan Pharmaceuticals, Inc., please visit www.kolltan.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.